Voyager Therapeutics Inc (VYGR)

Currency in USD
3.650
+0.260(+7.67%)
Closed·
3.600-0.050(-1.37%)
·
VYGR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
VYGR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.4103.770
52 wk Range
2.6458.275
Key Statistics
Prev. Close
3.65
Open
3.43
Day's Range
3.41-3.77
52 wk Range
2.645-8.275
Volume
1.28M
Average Volume (3m)
757.18K
1-Year Change
-44.7%
Book Value / Share
4.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VYGR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.667
Upside
+329.22%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Voyager Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Voyager Therapeutics Inc Company Profile

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company’s lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer’s disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich’s ataxia; and GBA1 gene replacement program to treat parkinson’s disease. In addition, it provides research program for the treatment of Huntington’s disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Voyager Therapeutics Inc Earnings Call Summary for Q4/2024

  • Voyager Therapeutics reported Q4 2024 EPS of -0.37, in line with expectations, but stock fell 8.82% to $3.62 in after-hours trading
  • Company maintains strong $332M cash position and $8.2B in potential milestone payments, with cash runway extending to mid-2027
  • VY1706 tau silencing gene therapy advanced to IND-enabling studies; IND submission expected in 2026 with initial tau PET data in H2 2026
  • CEO emphasized potential for gene therapy value creation despite setbacks; CMO highlighted need for multiple Alzheimer's treatment options
  • Market reaction reflects investor concerns over financial performance and growth prospects, despite strong cash position and pipeline progress
Last Updated: 11/03/2025, 22:42
Read Full Transcript

Compare VYGR to Peers and Sector

Metrics to compare
VYGR
Peers
Sector
Relationship
P/E Ratio
−1.9x−0.5x−0.5x
PEG Ratio
0.00−0.010.00
Price/Book
0.8x2.8x2.6x
Price / LTM Sales
4.8x8.3x3.3x
Upside (Analyst Target)
254.0%308.2%40.3%
Fair Value Upside
Unlock18.0%4.7%Unlock

Analyst Ratings

12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 15.667
(+329.22% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-0.57 / -0.53
Revenue / Forecast
5.20M / 9.50M
EPS Revisions
Last 90 days

VYGR Income Statement

People Also Watch

20.40
SRPT
+8.51%
2.56
INMB
+5.79%
254.81
AVAV
+1.72%
2.970
JSPR
+4.21%
7.09
ARVN
+4.42%

FAQ

What Stock Exchange Does Voyager Therapeutics Inc Trade On?

Voyager Therapeutics Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Voyager Therapeutics Inc?

The stock symbol for Voyager Therapeutics Inc is "VYGR."

What Is the Voyager Therapeutics Inc Market Cap?

As of today, Voyager Therapeutics Inc market cap is 202.46M.

What Is Voyager Therapeutics Inc's Earnings Per Share (TTM)?

The Voyager Therapeutics Inc EPS (TTM) is -1.85.

When Is the Next Voyager Therapeutics Inc Earnings Date?

Voyager Therapeutics Inc will release its next earnings report on 17 Nov 2025.

From a Technical Analysis Perspective, Is VYGR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Voyager Therapeutics Inc Stock Split?

Voyager Therapeutics Inc has split 0 times.

How Many Employees Does Voyager Therapeutics Inc Have?

Voyager Therapeutics Inc has 172 employees.

What is the current trading status of Voyager Therapeutics Inc (VYGR)?

As of 14 Aug 2025, Voyager Therapeutics Inc (VYGR) is trading at a price of 3.65, with a previous close of 3.65. The stock has fluctuated within a day range of 3.41 to 3.77, while its 52-week range spans from 2.65 to 8.28.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.